Contraceptive Vaginal Rings

ABSTRACT

Contraceptive vaginal rings (CVRs) contain sex steroids that diffuse through a plastic polymer ring at a constant rate and are absorbed directly through the vaginal epithelium into the systemic circulation. This delivery system provides many advantages over oral contraceptives (OCs), including avoidance of the first-pass effect through the liver, constant serum steroid levels, longer duration of use, and greater bioavailability of the hormones. CVRs containing progestin only are designed for continuous use for 3 to 6 months. Those containing progesterone alone are indicated for use in women who are breastfeeding. Large clinical trials of progestin-containing CVRs demonstrated good efficacy and safety of the CVR, with continuation rates similar to that of OCs. CVRs containing a combination of estrogen and progestin are designed to be used for 1 to 12 months in a cyclic manner similar to OCs, with withdrawal bleeding in the fourth week of each cycle. In clinical trials these CVRs have typical use efficacies similar to OCs, with an acceptable pattern of bleeding.

KEYWORD

Contraception - sex steroid hormones - vaginal ring

REFERENCES

• 1 Macht D. The absorption of drugs and poisons through the vagina.  Journal of Pharmacology Path . 1918;  10 509
• 2 Dzuik P, Cook B. Passage of steroids through silicone rubber.  Endocrinology . 1966;  78 208-211
• 3 Roumen F, Dieben T. Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring.  Contraception . 1999;  59 59-62
• 4 Timmer C, Apter D, Voortman G. Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings.  Contraception . 1990;  42 629-642
• 5 Landgren B, Johannisson E, Masironi B, Diczfalusy E. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.  Contraception . 1982;  26 567-585
• 6 Jackanicz T M. Levonorgestrel and estradiol release from an improved contraceptive vaginal ring.  Contraception . 1981;  24 323-339
• 7 Mishell D R, Talas M, Parlow A, Moyer D L. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate.  Am J Obstet Gynecol . 1970;  107 100-107
• 8 World Health Organization. Microdose intravaginal levonorgestrel contraception-a multicentre clinical trial I: contraceptive efficacy and side effects.  Contraception . 1990;  41 105-124
• 9 World Health Organization. Microdose intravaginal levonorgestrel contraception-a multicentre clinical trial IV: bleeding patterns.  Contraception . 1990;  41 151-167
• 10 Ji G, Hong-zhu S, Gui-ying S, Li-yuan M. Clinical investigation of a low-dose levonorgestrel-releasing vaginal ring.  Fertil Steril . 1986;  46 626-630
• 11 Bounds W, Szarewski A, Lowe D. Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring.  Eur J Obstet Gynecol Reprod Biol . 1993;  48 123-125
• 12 Diaz S, Jackanicz T, Herreros C. Fertility regulation in nursing women VIII: progesterone plasma levels and contraceptive efficacy of a progesterone-releasing vaginal ring.  Contraception . 1985;  32 603-621
• 13 Chen J, Wu S, Shao W. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women.  Contraception . 1998;  57 371-379
• 14 Sivin I, Diaz S, Croxatto H B. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD.  Contraception . 1997;  55 225-232
• 15 Mishell D R, Moore D E, Roy S, Brenner P F, Page M A. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.  Am J Obstet Gynecol . 1978;  130 55-62
• 16 Sivin I, Mishell D R, Victor A. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings I: use effectiveness.  Contraception . 1981;  24 341-358
• 17 Roy S, Krauss R M, Mishell D R, Casagrande J, Pike M C. The effect on lipids and lipoproteins of a contraceptive vaginal ring containing levonorgestrel and estradiol.  Contraception . 1981;  24 429-449
• 18 Robertson D, Alvarez F, Sivin I. Lipoprotein patterns in women in Santo Domingo using a levonorgestrel/estradiol contraceptive ring.  Contraception . 1981;  24 469-479
• 19 Ahren T, Lithell H, Victor A, Vessby B, Johansson E D. Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring II: serum lipoproteins and apolipoproteins.  Contraception . 1981;  24 451-467
• 20 Ahren T, Lithell H, Victor A, Vessby B, Johansson E D. Comparison of the metabolic effects of two hormonal contraceptive methods-an oral formulation and a vaginal ring I: carbohydrate metabolism and liver function.  Contraception . 1981;  24 415-427
• 21 Ahren T, Victor A, Lithell H, Vessby B, Jackanicz T M, Johansson E D. Ovarian function, bleeding control and serum lipoproteins in women using contraceptive vaginal rings releasing five different progestins.  Contraception . 1983;  28 315-327
• 22 Adams M, Clarkson T, Koritnik D, Nash H A. Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques.  Fertil Steril . 1987;  47 1010-1018
• 23 Ballagh S A, Mishell D R, Jackanicz T M, Lacarra M, Eggena P. Dose-finding study of a contraceptive ring releasing norethindrone acetate/ethinyl estradiol.  Contraception . 1994;  50 535-549
• 24 Ballagh S A, Mishell D R, Lacarra M, Shoupe D, Jackanicz T M, Eggena P. A contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol.  Contraception . 1994;  50 517-533
• 25 Weisberg E, Fraser I S, Lacarra M. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.  Contraception . 1999;  59 311-318
• 26 Weisberg E, Fraser I S, Mishell D R, Lacarra M, Darney P, Jackanicz T M. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.  Contraception . 1999;  59 305-310
• 27 Weisberg E, Fraser I S, Lacarra M, Mishell D R, Jackanicz T M. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring.  Contraception . 1997;  56 233-239
• 28 Laurikka-Routti M, Haukkamaa M, Heikinheimo O. A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry.  Contraception . 1990;  42 111-120
• 29 Alvarez-Sanchez F. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.  Contraception . 1992;  46 387-398
• 30 Apter D, Cacciatore B, Stenman U, Alapiessa U, Assendorp R. Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol.  Contraception . 1990;  42 285-295
• 31 Olsson S-E, Odlind V. Contraception with a vaginal ring releasing 3-keto desogestrel and ethinylestradiol.  Contraception . 1990;  42 563-572
• 32 Timmer C J, Mulders T M. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.  Clin Pharmacokinet . 2000;  39 233-242
• 33 Mulders T M, Dieben T. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.  Fertil Steril . 2001;  75 865-870
• 34 Roumen F, Apter D, Mulders T M, Dieben T. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl estradiol.  Hum Reprod . 2001;  16 469-475
• 35 Fraser I S, Weisberg E, Minehan E, Johansson E D. A detailed analysis of menstrual blood loss in women using Norplant℗ and Nestorone℗ progestogen-only contraceptive implants or vaginal rings.  Contraception . 2000;  61 241-251
• 36 World Health Organization. Microdose intravaginal levonorgestrel contraception-a multicentre clinical trial II: expulsions and removals.  Contraception . 1990;  41 125-141
• 37 Sivin I, Mishell D R, Victor A. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings II: subjective and objective measures of effects.  Contraception . 1981;  24 359-376
• 38 Schwan A, Ahren T, Victor A. Effects of contraceptive vaginal ring treatment on vaginal bacteriology and cytology.  Contraception . 1983;  28 341-347
• 39 Roy S, Wilkins J, Mishell D R. The effect of a contraceptive vaginal ring and oral contraceptives on the vaginal flora.  Contraception . 1981;  24 481-491
• 40 Fraser I S, Lacarra M, Mishell D R. Vaginal epithelial surface appearances in women using vaginal rings for contraception.  Contraception . 2000;  61 131-138
• 41 Faundes A, Hardy E, Reyes Q, Pastene L, Portes-Carrasco R. Acceptability of the contraceptive vaginal ring by rural and urban population in two Latin American countries.  Contraception . 1981;  24 393-414
• 42 Fu H, Darroch J E, Haas T, Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth.  Fam Plann Perspect . 1999;  31 56-63